Excavation · Do COVID-19 Vaccines Cause Cancer? The 'turbo cancer' claim (2020 to 2026)
Area: Medicine and Health · Media and Misinformation · Question: Is a widely shared claim true?, What caused it?, Where and when did it begin? · Starts from a widely shared claim
Source notices. Some sources this page discusses are retracted, corrected or unpublished.
The short answer
Leans no, leans moderately toward leans no
Current assessment · as of 2026-10-06
Leans no (moderate confidence). No study has measured 'turbo cancer'; registries show no surge; the two cohorts that report more cancer are disputed and their authors stop short of cause.
Which way the evidence leans: moderately toward no. This is not a finding.
Central claim: COVID-19 vaccination causes unusually rapid or aggressive cancers (called "turbo cancer") in vaccinated people.
Evidence ●○○○○ Public belief ●●●○○ Source checked: secondary
What would settle it. Not yet read, and listed as sub-questions of this question (claims cvc-sq-...): the Seoul journal's outcome on its notice of concern; the English national registry for 2021 to 2022; the 2026 US report in full; the Kruger interview and the "Died Suddenly" film by a human viewer; the randomised trials' supplementary adverse-event tables; the French cohort's cancer-specific result; the residual-DNA papers behind the FDA and EMA statements; and the cdc.gov and UK official pages. What would settle the question itself: a matched cohort that defines rapid progression in advance and compares vaccinated and unvaccinated people over several years (dt-rapid-progression-cohort), a registry-linked analysis with individual vaccination status (dt-registry-linked-incidence), and a replication of the Seoul analysis with a common start date and a lag period (dt-lag-analysis).
The term "turbo cancer" means cancers that appear or progress unusually fast after COVID-19 vaccination. We found no controlled study that defines such cancers in advance and compares them between vaccinated and unvaccinated people (cvc-rapid-progression-gap), so the claim has never been tested directly. What can be checked is indirect. National cancer series for the United States and Japan show a drop in diagnoses in 2020, when screening was disrupted, and a return toward earlier levels by 2021 to 2022; overall age-standardised cancer death rates kept falling (cvc-no-registry-surge). Those are population totals with no vaccination status, so they cannot rule out a rise in a small group, and the same totals cannot show cause in either direction. Two cohort studies compared vaccinated with unvaccinated people. A Seoul study of adults (a Letter in Biomarker Research, September 2025) reports a hazard ratio of 1.27 for any cancer within one year, and an Italian study of Pescara province residents aged 11 and over reports 1.23 for hospital admission with cancer. The Seoul authors write that their findings do not establish causal relationships; the Italian authors call theirs preliminary because healthy-vaccinee bias and unmeasured confounders could not be quantified. Two published commentaries point to different start dates for the two groups and a low-incidence comparison group in the Seoul study; in the Italian study the authors' own sensitivity analysis shows the one-dose association no longer significant, and the three-dose hazard ratio below 1, when a 365-day minimum lag is used; and the journal has carried a notice of concern on the Seoul letter since October 2025, with no outcome yet (cvc-cancer-incidence-higher-after-vaccination). A Japanese paper that reported excess cancer deaths after the third dose was retracted in June 2024. Case reports describe individual patients whose cancer appeared or progressed after vaccination, but they have no comparison group and their compilers say they cannot show how often this happens. Laboratory work shows a spike-protein effect on p53 in two engineered cell lines, which its authors call preliminary. A mouse case report that was widely shared as proof carries an addendum in which its authors reject the "turbo cancer" reading. Statistics cannot prove a general claim false, so "vaccines cause cancer" and "vaccines cause turbo cancer" are filed as proposed, not refuted. What health bodies and politicians say, in both directions, is shown separately as adoption, not evidence: NCI, EMA, the American Cancer Society and ASCO say there is no evidence of a link; a Florida official, two members of a CDC advisory workgroup and a Senate subcommittee chair have said the opposite or called for more study. The FDA label says the vaccine has not been evaluated for carcinogenicity, which is neither a finding of harm nor of safety.
Registries show no surge in all-cancer rates after the rollout, no controlled study has found rapid progression after vaccination, the two cohorts that report more cancer have documented design problems and in one the one-dose association is no longer significant at a 12-month lag (breast and bladder stay raised), and the mechanism work is in cell lines.
Why the lean is not a finding. Population totals cannot see a rise in a small group. No study has tested the claim as its proponents state it. The two cohorts cannot be set aside as noise, and the Seoul letter's concern notice is unresolved. Absence of a finding is a state of the search, not proof of absence.
Based on: cvc-rapid-progression-gap cvc-no-registry-surge cvc-cancer-incidence-higher-after-vaccination cvc-korea-cohort-bias-concerns cvc-italy-cohort-lag cvc-case-reports-no-denominator cvc-gibo-paper-retracted cvc-mechanism-spike-p53
We give no probability figure. Confidence words describe how sure we are of the basis, and no source supplies a number that would not be invented.
Challenge this assessment A challenge needs a specific claim and evidence we can check. How challenges work.
established confidence moderate · our conclusion
In the national cancer series we read for the United States and Japan, age-standardised all-cancer incidence fell in 2020 and returned toward earlier levels by 2021 to 2022, and age-standardised all-cancer mortality kept falling to 2023 or 2024, so these series show no surge in cancer after the 2021 vaccine rollout beyond long-running trends at particular sites.
Anchor. US: Sherman et al., Annual Report to the Nation 2025 (Cancer 2025, read in full): incidence 2017-2019 and 2021 aggregate 461.3 per 100,000, 2020 425.6; joinpoint all sites 2012-2021 annual percent change 0.1 (95% CI -0.1 to 0.3); mortality 2018-2022 146.0, average annual change -1.5; joinpoint 2016-2019 -2.1 and 2019-2022 -1.3, "slowing" but not reversing; the 2026 report (abstract and CDC release only) reports mortality 2019-2023 falling 1.6 per year in men and 1.1 in women and incidence rising slightly 2018 to 2022, "driven by increases in breast cancer among women and prostate cancer among men" (wording as recorded from the CDC release, which was not opened by the independent reviewer; it is not in the abstract). Japan: National Cancer Center files read directly: age-standardised all-cancer mortality, both sexes, 278.9 (2019), 276.8 (2020), 275.0, 273.9, 268.4, 266.7 (2024); registry incidence 282.1 (2019), 263.6 (2020), 275.7, 271.9, 272.5 (2023). Not flat at every site: Japanese female breast cancer mortality rose from 20.6 to 21.9 in 2022 and fell to 21.3 in 2023; leukaemia rose from 6.7 to 7.1 in 2022 and stayed there; pancreas has risen steadily since 2010. We did not test breakpoints at the vaccine rollout ourselves.
Would change if. a later year of the US or Japanese series, or the English registry, shows an age-standardised all-cancer rise that cannot be traced to a long-running site trend; or an analysis with individual vaccination status finds a rise in a subgroup that totals hide
The question is resolvable in principle (a matched cohort with a pre-defined outcome would answer it) and has not been answered. This dig keeps five things apart: (1) the direct tests, two cohort studies, filed as `synthetic` evidence with their disputes; (2) the population registry series, which are ecological and cannot see individual exposure; (3) case reports and laboratory work, which are filed with what they cannot show; (4) a retracted paper and a mouse case report, whose authors reject the "turbo cancer" reading, that circulated as proof; and (5) the institutional record, filed as adoption in both directions, never as evidence. Scope was set by the owner to the popular claim of rapidly progressing cancers after vaccination ("turbo cancer"), with a timeline.
The reach of this claim and the evidence for it come apart. Online, the phrase "turbo cancer" was reported by one monitoring vendor (not audited) as about 1.6 million English-language posts and 22 billion impressions from November 2022 to November 2024. From 2023 to 2026 the idea was linked, by a CBS-quoted physician, to a Florida surgeon general's January 2024 recommendation to providers (his documents themselves do not use the term), and the debate reached two slides at a CDC advisory meeting (September 2025), a Senate subcommittee hearing and a few review papers; the same period produced official statements that there is "no evidence" of a link. None of that is evidence either way. The evidence is thinner than either side's reach: no controlled study has measured rapid progression by vaccination status; two cohorts report a modest excess and are disputed; registry totals show no surge; case reports and cell-line work cannot bear the weight put on them. The open edge is the unmeasured part: a rise in a small subgroup would not show in all-cancer registry rates, and the study that would see it has not been done. Strata records the gap and gives the crowd, on every side, no evidential weight.
Every point on the timeline links to its source. Open the timeline.
Status: passed with open items · reviewed 2026-10-06. Round 2, PR #14, head 2e92135 (author commits 5e846c7 and 2e92135 since round 1 at 427ee22). Fresh independent reviewer; read docs/REVIEW.md, docs/PUBLISH_GATE.md, the round-1 record and verdict, the author's response and git diff 427ee22..HEAD. The author changed only claims.yaml and log.yaml; the log gains L-13 and earlier entries are untouched (no removed lines in the log diff). Conformance on the merge with origin/main (merge --no-commit, then aborted): 0 errors; 2 warnings for this subject (no taxonomy entry; a key point over 170 characters, new in this round). review_dig.py: every mechanical check passes except the taxonomy entry. Sources re-opened by me this round: Acuti Martellucci 2025 (Europe PMC XML PMC12381369: "not significant anymore", HR 0.90, breast and bladder sentence, "inevitably preliminary"), Malatesta et al. 2025 (PMC12853024: "could also be due to factors unrelated to actual increases"), Eens addendum (PMC10622962: "unequivocally disassociate ourselves from this term") and the CDC release of 22 Sep 2026 (src-cdc-arn-2026-release, opened through WebFetch; curl returned 403; the "driven by increases in breast cancer among women and prostate cancer among men" sentence is on the page), which round 1 could not open. All seven round-1 requests are answered; the three blocking ones are fixed and verified against the sources, so each is resolved: true (author responses transcribed from the PR comment and L-13, since the author did not edit this owner-only file). Surface lines re-read against the claims: the headline is unchanged; search_summary, the assessment, short answer and key points say no more than the claims; adoption is not in the basis. Three non-blocking requests are added as round 2. Status passed_with_open_items; the owner publishes (site.yaml untouched by me). Round 1 notes follow, unchanged. Round 1, PR #14, head 3e2bb7a. The reviewer edited only this file and did not add the subject to build/site.yaml. Conformance on the merge with origin/main (git merge --no-commit, then aborted): 0 errors; 1 warning for this subject (no taxonomy entry). review_dig.py: every mechanical check passes except the taxonomy entry; 10 quotes matched in stored text, 47 not (the stored texts cover few sources), so the quotes below were checked by hand in the sources themselves. Opened and read by the reviewer (25 of 93 manifest sources): Eens 2023 (Europe PMC XML) and its addendum; FactCheck.org 31 Aug 2023; Gibo 2024 (Europe PMC XML) and the retraction notice (PMC11204115, dated 26 Jun 2024); the PubMed record of the Cureus expression of concern (title, type and date 12 Jun 2024 only, as in the manifest); the COMIRNATY prescribing information (fda.gov PDF, sha256 matches the manifest; Revised 8/2026; section 13.1 sentence verbatim); Annual Report to the Nation 2025 (Europe PMC XML: 461.3, 425.6, about 8 percent lower, 146.0, -1.5, 2021 "returned to prepandemic levels"); the 2026 report abstract (PubMed); the SEER 2026 statistics page; both National Cancer Center Japan workbooks (sha256 of both match; all-site mortality 278.9, 276.8, 275.0, 273.9, 268.4, 266.7 for 2019 to 2024 and incidence 282.1, 263.6, 275.7, 271.9, 272.5 confirmed; breast and leukaemia figures confirmed); Kim 2025 letter (Europe PMC XML; Change history notice of 22 Oct 2025 present; PubMed type Letter; Crossref shows no update-to relation) and all three additional files (sha256 of all three match; HR 1.27, 1.21 to 1.33; 42.62 against 33.43; 1.472, 1.339, 1.199; 77.22 percent; index date 1 Jan 2022 for the unvaccinated; "our findings do not establish causal relationships"; "reverse causation or surveillance bias cannot be excluded"); Acuti Martellucci 2025 (Europe PMC XML: 296,015; HR 1.23 and 1.09; 365-day sensitivity; "inevitably preliminary"; "represent only a proxy of the total new cases of cancer"); Zhang and El-Deiry 2024; Locquet 2026; Kuperwasser and El-Deiry 2026; NCI page; EMA key facts page; Hecht's Substack post (live page; datePublished 2022-08-04; Kruger and "by nature anecdotal" quotes found); Dalgleish and Gralow written testimony (hsgac.senate.gov PDFs; "no doubt" sentence and its context, "no clinical evidence proving", "does not develop suddenly" found); Malatesta et al. 2025 letter and the two 2026 EXCLI items (PMC12853024, PMC13139733, PMC13139735). Required sample (REVIEW.md A): the refuted claim cvc-eens-proved-turbo-cancer (all three anchors opened, passages found, match); headline claim cvc-no-registry-surge (five of six anchors opened and matched; src-cdc-arn-2026-release not checked: cdc.gov returned 403 and the Wayback copy reset the connection, so the quoted words "driven by increases in breast cancer among women and prostate cancer among men" are unverified by me; the SEER page I read does support the substance, female incidence rising 0.4 percent a year 2011 to 2022 and prostate rising); weight-5 claims cvc-gibo-paper-retracted and cvc-fda-label-not-evaluated (opened, match; the expression-of-concern text was not read by me or the author, and the claim says so). Rule 9 and classes: the one refuted claim names its target (the post text, confirmed in FactCheck.org's citation of @DiedSuddenly_, 18 Aug 2023) and rests on the authors' addendum, primary text; narrative_drift fits. The general claims stay proposed and statistics refute nothing. Every searched gap carries absence_anchor and is provisional; no unmarked absence claim above provisional found. Retracted and flagged papers: Gibo is RETRACTED in source_notices, on its claim and on all three timeline events; the Kim letter's notice of concern is in source_notices and flagged on every claim and test that cites it; the Eens addendum is shown. These are prominent and correct. No percentage in the assessment; exactly three key points. Rights: quotations are short and attributed. Fairness (D): the Seoul and Pescara authors and their critics are each read in full and quoted at their own words; competing interests are noted on both sides (El-Deiry, Locquet). Three blocking requests and four non-blocking ones are in round 1 below. All blocking items are wording fixes; no weight or state needs to move. The review record.
refuted: the claim below is false confidence high · what a source says
The Eens et al. 2023 mouse case report proved that Pfizer's mRNA vaccine induced "turbo cancer".
Anchor. The paper is a case report of one mouse in which the authors write that "a demonstration of direct causality remains difficult". Their addendum of 20 Oct 2023 says: "we wish to unequivocally disassociate ourselves from this term. In our case report, there is not a single reference to a condition called 'turbo cancer', nor do we recognize it as a legitimate medical term"; the vaccine was given intravenously at high dose in a myocarditis-model replication.
Would change if. the authors retract their addendum, or the paper is shown to say what the posts claimed
established confidence moderate · our conclusion
In the national cancer series we read for the United States and Japan, age-standardised all-cancer incidence fell in 2020 and returned toward earlier levels by 2021 to 2022, and age-standardised all-cancer mortality kept falling to 2023 or 2024, so these series show no surge in cancer after the 2021 vaccine rollout beyond long-running trends at particular sites.
Anchor. US: Sherman et al., Annual Report to the Nation 2025 (Cancer 2025, read in full): incidence 2017-2019 and 2021 aggregate 461.3 per 100,000, 2020 425.6; joinpoint all sites 2012-2021 annual percent change 0.1 (95% CI -0.1 to 0.3); mortality 2018-2022 146.0, average annual change -1.5; joinpoint 2016-2019 -2.1 and 2019-2022 -1.3, "slowing" but not reversing; the 2026 report (abstract and CDC release only) reports mortality 2019-2023 falling 1.6 per year in men and 1.1 in women and incidence rising slightly 2018 to 2022, "driven by increases in breast cancer among women and prostate cancer among men" (wording as recorded from the CDC release, which was not opened by the independent reviewer; it is not in the abstract). Japan: National Cancer Center files read directly: age-standardised all-cancer mortality, both sexes, 278.9 (2019), 276.8 (2020), 275.0, 273.9, 268.4, 266.7 (2024); registry incidence 282.1 (2019), 263.6 (2020), 275.7, 271.9, 272.5 (2023). Not flat at every site: Japanese female breast cancer mortality rose from 20.6 to 21.9 in 2022 and fell to 21.3 in 2023; leukaemia rose from 6.7 to 7.1 in 2022 and stayed there; pancreas has risen steadily since 2010. We did not test breakpoints at the vaccine rollout ourselves.
Would change if. a later year of the US or Japanese series, or the English registry, shows an age-standardised all-cancer rise that cannot be traced to a long-running site trend; or an analysis with individual vaccination status finds a rise in a subgroup that totals hide
established confidence high · what a source says
Kim et al. (Biomarker Research, 26 Sep 2025, a Letter) report that among 2,975,035 matched Seoul adults aged 20 and over in the Korean national health insurance database, vaccinated people had more first cancer diagnoses in one year of follow-up than unvaccinated people: overall hazard ratio 1.27 (95% CI 1.21 to 1.33), 42.62 against 33.43 per 10,000 at one year. Site hazard ratios were 1.351 (thyroid), 1.335 (gastric), 1.283 (colorectal), 1.533 (lung), 1.197 (breast) and 1.687 (prostate).
Anchor. Kim HJ, Kim MH, Choi MG, Chun EM, Biomark Res 2025;13:114 (received 11 Jul 2025, accepted 21 Aug 2025), PubMed type Letter. Not "national": the cohort is Seoul residents. 8,407,849 screened (679,479 unvaccinated, 7,728,370 vaccinated); after exclusions and 1:4 greedy propensity matching, 595,007 unvaccinated and 2,380,028 vaccinated; index date 1 Jan 2022 for the unvaccinated and the day after finishing the primary series for the vaccinated; one-year follow-up; matching on age, sex, income proxy, Charlson index and prior SARS-CoV-2 infection (77.22 percent in both groups). The overall figure is in the additional files; the letter's abstract gives site hazard ratios. Cumulative incidence per 10,000 at 1 month 2.91 against 1.63, at 1 year 42.62 against 33.43. By vaccine type, overall hazard ratio: adenoviral only (the paper's "cDNA vaccine" group) 1.472, heterologous 1.339, mRNA only 1.199. Booster against no booster (n=1,067,688): overall 1.01 (0.95 to 1.06), pancreatic 2.25 (1.44 to 3.50), leukaemia 0.56 (0.35 to 0.92). Authors' limits (Additional File 2): "our findings do not establish causal relationships"; one-year follow-up is short for solid tumours and "the possibility of reverse causation or surveillance bias cannot be excluded".
Would change if. the journal corrects or retracts the letter, or the Additional Files differ from the PMC copy read
established confidence high · what a source says
Acuti Martellucci et al. (EXCLI Journal, July 2025) report that in 296,015 residents of Pescara province aged 11 and over, first hospital admission with cancer was more frequent after at least one dose (hazard ratio 1.23, 1.11 to 1.37) and three or more doses (1.09, 1.02 to 1.16) than with none, and that with a 365-day minimum lag the one-dose association was not significant overall and the three-dose hazard ratio was 0.90 (0.83 to 0.98); the paper adds that at 365 days "breast and bladder cancer hospitalizations maintained their positive association with ≥1 dose".
Anchor. Acuti Martellucci C et al., EXCLI J 2025;24:690-707, DOI 10.17179/excli2025-8400. Follow-up to 31 Dec 2023; the unvaccinated were followed from 27 Jun 2021 (one-dose comparison) or 26 Dec 2021 (three-dose comparison) and the vaccinated from 180 days after the first (or third) dose, a 180-day minimum lag between exposure and outcome (90 and 365 days as sensitivity runs). Unvaccinated 49,265, at least one dose 246,750, three or more 183,999. Outcome: first admission with a cancer diagnosis in the regional discharge database (skin cancer excluded; people with a prior admission for the same cancer in the previous ten years excluded), not registry incidence; 3,134 admissions. Cox models adjusted for age, sex, prior infection, diabetes, hypertension, cardiovascular disease, COPD, kidney disease and prior cancer admission; no smoking, screening or healthcare-use data. Crude proportions 0.85 percent (unvaccinated) and 1.15 percent (at least one dose). Without a recorded prior infection the hazard ratios were 1.31 (1.16 to 1.47) and 1.11 (1.03 to 1.20). Breast, bladder and colorectal were raised at one dose; lung, ovary and thyroid were not. By sex, the raised risk was seen only in men with at least one dose (1.31, 1.12 to 1.52). All-cause death hazard ratio 0.42 (0.39 to 0.44) for at least one dose, which the authors ascribe to healthy-vaccinee bias. The authors write: "Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary." Letters: Malatesta et al. argue the mortality result reflects immortal-time bias; Manzoli et al. reply that age-adjusted models align time zero. Their main argument is about mortality; Malatesta et al. also note that the excess of tumours "could also be due to factors unrelated to actual increases".
Would change if. the authors or a critic publish a corrected analysis that changes the figures
established confidence high · our conclusion
Both cohorts compare people who chose to be vaccinated with people who did not, take their outcomes from claims or hospital records and not from cancer registries, and have no data on smoking or screening; the Seoul authors state that the results do not establish cause and the Pescara authors call theirs preliminary.
Anchor. Seoul: outcome is the first primary diagnosis of cancer in insurance claims; Additional File 2 says "the possibility of reverse causation or surveillance bias cannot be excluded". Pescara: outcome is hospital admission with a cancer diagnosis, which the authors say "represent only a proxy of the total new cases of cancer"; smoking unknown. Pescara's all-cause death hazard ratio of 0.42 for at least one dose, which no one reads as a protective effect of that size, is the authors' own evidence that bias between vaccinated and unvaccinated groups in this setting is large (our reading; the authors say so for mortality). Neither study can say whether cancers were found earlier because vaccinated people use more healthcare, or found later because they did not.
Would change if. a cohort with randomised or registry-verified exposure and outcome, and data on screening, is published
established confidence high · our conclusion
Published case reports and small series of cancers appearing, recurring or progressing after COVID-19 vaccination describe individual patients; they have no comparison group and no denominator, so they cannot show how often this happens or whether it is more than expected.
Anchor. Kuperwasser C, El-Deiry WS, Oncotarget 2026 (3 Jan 2026): 69 publications (January 2020 to October 2025 per the abstract), 66 article-level reports of 333 patients in 27 countries; reports of lymphomas, leukaemias, breast, lung, melanoma, sarcoma, pancreas, glioma, Kaposi and Merkel; recurring themes of "unusually rapid progression, recurrence, or reactivation". The review also covers cancers after infection. Its authors' limits: most reports are single-patient descriptions or small series, "highly susceptible to publication bias and selective reporting", and the review is "not designed to estimate cancer risk or incidence, nor to draw causal inferences". The authors report searching PubMed, Scopus, Web of Science, Google Scholar and React19 (their abstract calls it a systematic search) and, after PubMed keyword searches returned little, an expanded search with general web queries; the abstract gives the search period as January 2020 to October 2025 and the results text as January 2020 to April 2025. The Editor-in-Chief, El-Deiry, is also an author, was not involved in the peer review, and emailed the manuscript to the NCI Director on 12 Dec 2025 (editorial note in the paper).
Would change if. a registry-linked analysis of the same cancer types shows the reported patterns more often in vaccinated than unvaccinated people
established confidence high · what a source says
Goldman et al. (Frontiers in Medicine, 2021) report one 66-year-old man with angioimmunoblastic T-cell lymphoma whose whole-body total lesion glycolysis was 5.3 times higher on a second PET scan 22 days after the first, 8 days after a booster dose, with new lesion sites; the authors call the progression "highly unexpected" and say extrapolating to other patients is premature.
Anchor. Goldman S et al., Front Med 2021;8:798095. Biopsy after a PET/CT on 8 Sept 2021 showing stage IV-pattern disease; two vaccine doses 5 to 6 months earlier; booster 14 days after the first PET; steroids started right after; antibody titres unchanged. The authors write that it is "reasonable to postulate" the booster was the trigger, and also that extrapolation of the findings to other patients is premature; no comparison patients. Our observation, not the authors': the same 22 days include an untreated aggressive lymphoma, a flu-like illness at presentation, and a short interval between scans.
Would change if. not applicable: a report of one patient; a cohort would test the pattern
established confidence high · what a source says
Eens et al. (Frontiers in Oncology, 1 May 2023) report one BALB/c mouse, one of a group of 14 given high-dose intravenous BNT162b2 in a myocarditis model, that was found dead two days after the booster with a B-cell lymphoblastic lymphoma; the authors say "a demonstration of direct causality remains difficult" and, in an addendum, that over 70 other BALB/c mice they injected did not develop haematologic malignancy.
Anchor. Eens S et al., Front Oncol 2023;13:1158124 (PMID 37197431). Single mouse; CD19-, TdT- and c-MYC-positive lymphoid neoplasm; vaccination intravenous (not intramuscular) and high dose; found dead two days after the booster at 14 weeks. Addendum (doi 10.3389/fonc.2023.1267904, 20 Oct 2023): "we have injected over 70 BALB/c mice ... Excluding the published case report, none of these other vaccinated animals developed hematologic malignancies of any type"; spontaneous lymphoma is known in the strain; "case reports ... do not test correlation between variables, nor are they used to demonstrate causality". FactCheck.org (2023-08-31, secondary) says 1 of 14 high-dose mice died of lymphoma.
Would change if. the journal retracts the paper or the authors publish further animal data
established confidence high · what a source says
In 2020 new cancer diagnoses fell sharply in many countries because of disrupted screening and care, and then returned toward expected levels; this complicates any reading of cancer counts from 2020 onward.
Anchor. US (Annual Report to the Nation 2025, read in full): 2020 incidence 425.6 against 461.3 for the other years, about 8 percent lower; earlier reports cited 2020 diagnoses "9%-10% lower than expected overall", with screenable sites (prostate rate ratio 0.83 to 0.86, thyroid about 0.81, lung 0.86 to 0.87) falling most; the authors write that "additional data years are needed to correctly interpret this decline and assess whether cases went undiagnosed or underreported, because the rates in 2021 were not greater than expected". Japan: registry incidence 282.1 (2019) to 263.6 (2020), 275.7 in 2021, still below 2019 in 2022 and 2023; Abstract-level: US Bayesian model 6.7 percent fewer cases than expected in 2020 to 2022 and "substantial numbers of unaccounted-for cases remained"; seven-country benchmarking, 16 percent deficit April to December 2020; England prostate down 31 percent in 2020 and back to expected by 2022; Nordic first-wave declines of 7.9 to 21.7 percent; Hungary 12.8 percent lower in men.
Would change if. a later series shows the 2020 deficit was not recovered or was larger than recorded
established confidence high · what a source says
A US military surveillance report counted incident non-Hodgkin lymphoma in active-duty service members as 40, 34, 30, 29, 30, 38 and 43 cases in 2017 to 2023 (rates 3.0, 2.5, 2.2, 2.1, 2.2, 2.8 and 3.3), mentions no vaccination and attributes nothing to it; a 2026 review cites it as a "~50% increase" (2.2 in 2021 to 3.3 in 2023), while 2023 is 10 percent above 2017.
Anchor. Non-Hodgkin lymphoma incidence in active component U.S. service members, MSMR 2025 (PMID 40019944), Defense Medical Surveillance System, 621 incident cases 2017-2023; "Specified and unspecified NHL" counts and rates as above; mature T/NK counts 9, 13, 9, 8, 17, 14, 14. The report notes a "modest increase". The units are inconsistent inside the document (table footnote per 10,000 person-years, text per 100,000). Counts are in the tens. The 10 percent figure is Strata's own arithmetic from 3.0 and 3.3.
Would change if. the report is revised or a later report attributes the change to a cause
established confidence high · what a source says
A 2024 Cureus paper by Gibo et al. reporting excess age-adjusted cancer mortality in Japan after the third mRNA dose (2.1 percent above an extrapolated line in 2022) was retracted on 26 June 2024 after an expression of concern on 12 June, with the editors writing that the correlation between mortality rates and vaccination status cannot be proven with the data presented; the authors disagree, and the paper is still cited as support.
Anchor. Retraction notice, Cureus 2024 (doi 10.7759/cureus.r143), read in the Europe PMC copy: "The Editors-in-Chief have retracted this article. Upon post-publication review, it has been determined that the correlation between mortality rates and vaccination status cannot be proven with the data presented in this article. As this invalidates the conclusions of the article, the decision has been made to retract. The authors disagree with this retraction." The paper (doi 10.7759/cureus.57860): descriptive ecological time-series of Japanese vital statistics, logistic extrapolation of 2010-2019 (10 points) to predict 2020-2022, no individual vaccination status (vaccination coverage appears only as a monthly series), 20 cancer types tested with no multiplicity correction described; excess for all cancers -0.4 (2020), 1.1 (2021) and 2.1 (2022), 7,162 excess deaths in 2022 (95% CI 4,786 to 9,522); observed all-cancer age-adjusted rates 275.5, 275.8 and 274.6 per 100,000, so the observed rate did not rise in 2022. Its own limits: "has not been clinically validated"; further analytical statistics by vaccination status are needed. The paper also notes that 2020 screening fell. Cureus pages returned 403 here; the expression-of-concern text was not read.
Would change if. the journal reverses the retraction
established confidence moderate · what a source says
Zhang and El-Deiry (Oncotarget, May 2024) report that in two human cell lines lacking p53 (U2OS p53-knockout and HCT116 p53-null) given wild-type p53, spike protein expressed from a plasmid reduced MDM2-p53 co-precipitation and p53 reporter activity and blunted the rise of p21, DR5 and MDM2 after cisplatin or nutlin; the authors did not detect spike bound to p53, saw no cell-cycle arrest, and call the observations preliminary.
Anchor. Zhang S, El-Deiry WS, Oncotarget 2024 (PMID 38709242; received 16 Apr, accepted 30 Apr 2024). Plasmid pcDNA3.1-SARS2-spike transfected into cancer cell lines with co-transfected wild-type p53; effects on co-immunoprecipitation, a PG13-luciferase reporter and downstream proteins; cisplatin-treated spike cells had higher viability. The paper frames its finding as a possible mechanism for SARS-CoV-2 infection and chemotherapy sensitivity, not for vaccination. Authors: "did not detect SARS-CoV-2 spike bound with p53", "preliminary observations ... warrant further studies". Competing interest in the paper: the corresponding author is cofounder of Oncoceutics, p53-Therapeutics and SMURF-Therapeutics. A 2026 hypothesis paper by El-Deiry (PMID 41498241) adds an anecdote of a recurrence after vaccination relayed from a third party.
Would change if. the effect is replicated in vaccinated animals or in tumour tissue from vaccinated patients (it would strengthen), or fails to replicate in an independent laboratory (it would weaken)
established confidence high · what a source says
The FDA prescribing information for COMIRNATY (revised August 2026), section 13.1, says: "COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility."
Anchor. Section 13.1 of the prescribing information, read in the FDA copy (https://www.fda.gov/media/151707/download, formula 2026-2027, revised 8/2026); excerpt saved in sources/. The sentence says "not evaluated".
Would change if. the label is revised to report such an evaluation
established confidence high · what a source says
The US National Cancer Institute (page updated 10 Oct 2023), the European Medicines Agency (page dated 8 Apr 2026), the American Cancer Society (2024 version of its page) and ASCO (written testimony, 3 Jun 2026) each state that there is no evidence, information or clinical evidence that COVID-19 vaccines cause cancer.
Anchor. NCI: "There is no evidence that COVID-19 vaccines cause cancer, lead to recurrence, or lead to disease progression. Furthermore, COVID-19 vaccines do not change your DNA". EMA: "There is no evidence that COVID-19 vaccines may cause side effects, such as cancer, in the long term" and "No side effects linked to gene mutations, such as cancer, have been observed after vaccination with mRNA vaccines". ACS (Last Revised 9 Sep 2024, Wayback): "There is no information that suggests that COVID-19 vaccines cause cancer." ASCO (Gralow): "Currently, there is no clinical evidence proving that mRNA COVID-19 vaccines cause cancer". The live ACS page (revised 24 Sep 2025) no longer has that section; we do not know why (cvc-sq-acs-wording-change). We found no WHO, current CDC or UK statement on the question (cvc-sq-who-cdc-uk-statements).
Would change if. an agency page is revised or withdrawn
established confidence high · what a source says
On 14 December 2023 the FDA's CBER director Peter Marks replied to Florida Surgeon General Ladapo that "with over a billion doses of the mRNA vaccines administered, no safety concerns related to residual DNA have been identified" and that "there is nothing to indicate harm to the genome, such as increased rates of cancers".
Anchor. Marks to Ladapo, 14 Dec 2023 (read in the FDA PDF; text saved in sources/): residual DNA fragments reaching the nucleus and chromosomes is "quite implausible"; the 2007 plasmid DNA vaccine guidance "was developed for DNA vaccines themselves, not for DNA as a contaminant in other vaccines, and is not applicable to the mRNA COVID-19 vaccines". Points to global surveillance data and animal studies (FDA documents 151733 and 155931, not opened).
Would change if. the letter is withdrawn or the surveillance data it cites are shown not to support it
established confidence high · what a source says
On 6 December 2023 Florida Surgeon General Ladapo wrote to the FDA that "DNA integration could theoretically impact a human's oncogenes", quoting the 2007 guidance, and on 3 January 2024 his department said that if DNA integration risks "have not been assessed", mRNA vaccines "are not appropriate for use in human beings"; neither document reports a cancer case or uses the phrase "turbo cancer".
Anchor. Letter of 6 Dec 2023 to FDA Commissioner Califf (Wayback copy; floridahealth.gov returned 403): "The presence of SV40 promoter/enhancer DNA may also pose a unique and heightened risk of DNA integration into host cells"; three questions about integration and mutagenesis. Release of 3 Jan 2024 (Wayback copy): "DNA integration poses a unique and elevated risk to human health and to the integrity of the human genome"; providers should "prioritize patient access to non-mRNA COVID-19 vaccines and treatment". The word "cancerous" appears only in the quoted 2007 guidance.
Would change if. the department publishes data on cancer in vaccinated people
established confidence moderate · what a source says
At the CDC's ACIP meeting of 18-19 September 2025, two workgroup participants, Wafik El-Deiry and Charlotte Kuperwasser, presented slides saying "Cancers have been reported in mRNA vaccinated individuals in temporal association to immunization" and listing "Genomic integration in tissues or tumors in vaccinated patients" among gaps in knowledge; the slides do not use the phrase "turbo cancer".
Anchor. Workgroup slides dated 19 Sep 2025, read in a Wayback copy (cdc.gov blocked here), PDF created 18 Sep 2025: lists case reports (38 case reports and a study of 96 pancreatic cancer outcomes against IgG4) and states residual DNA "Exceeds limits by ~36-153-fold" for the Pfizer vaccine. The slides were not stored in this dig's sources folder (rights not checked), so quotations are marked for manual check.
Would change if. the slides are shown to differ from the Wayback copy read
established confidence moderate · what a source says
On 3 June 2026 the Senate Permanent Subcommittee on Investigations, chaired by Sen. Ron Johnson, held a hearing titled "Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications and Research"; the written statements read contain no new cancer data and none uses the phrase "turbo cancer".
Anchor. Witnesses: Dalgleish, El-Deiry, Hazan, Mostert, Malhotra, Gralow (ASCO), Felder. Johnson's opening is about media and pharma influence and "attacks on scientific publications"; Dalgleish (written): "I have no doubt in my mind that the mRNA vaccine likely played a significant role in the development of these unexpected cancers", from clinical observations without data tables; El-Deiry: the literature review and p53 experiments, and a PubPeer complaint; Gralow: no clinical evidence proving a link; Blumenthal: "the idea that a rollout of COVID-19 vaccines has precipitated a surge in cancer is simply not supported". Johnson's release of 5 Jun 2026 says the hearing "exposed the corruption" and cites "over 39,000 deaths" associated with the injection (source not given). Oral testimony and Q&A not read (no transcript found).
Would change if. the oral testimony or a committee report contains data not in the written statements
established confidence moderate · what a source says
The earliest document we read that uses "turbo cancer" about COVID-19 vaccines is Etana Hecht's Substack post "Turbo-Cancer" of 4 August 2022, a summary of an interview with the Swedish pathologist Ute Kruger; two earlier write-ups of the same interview (27 and 28 July 2022) say "aggressive and unusual cancers" and not "turbo".
Anchor. Hecht (Wayback copy of etana.substack.com/p/turbo-cancer): "Dr. Kruger initially thought that these turbo cancers, as she calls them"; she writes that she "hate[s] the title" and that Kruger's testimony is "by nature anecdotal". Global Research republication, metadata 8 Aug 2022. RAIR Foundation (27 Jul 2022) and myMedicalFreedom (28 Jul 2022) text-searched: no "turbo". Later amplification: DailyClout Report 61 (10 Mar 2023) titled with "Turbo Cancers". Secondary: Gorski (SBM, 19 Dec 2022) says he could not find who coined the term and cites an ar15.com comment of 30 Nov 2020 that we could not open. Whether Kruger herself used the term in the interview video is not verified (video not watched).
Would change if. an earlier document using the phrase about COVID-19 vaccines is found (cvc-sq-term-origin-earlier)
contested confidence low · our conclusion
COVID-19-vaccinated people are diagnosed with cancer more often than unvaccinated people (hazard ratio 1.27 in a Seoul cohort and 1.23 for cancer hospital admission in a Pescara cohort), and this reflects the vaccination and not how the groups were defined and followed.
Anchor. Seoul: Kim et al., Biomarker Research 2025;13:114 (a Letter), Korean National Health Insurance claims, Seoul residents aged 20 and over, 595,007 unvaccinated and 2,380,028 vaccinated after 1:4 propensity matching; one-year follow-up; any cancer hazard ratio 1.27 (95% CI 1.21 to 1.33); the authors write "our findings do not establish causal relationships" (Additional File 2). Pescara: Acuti Martellucci et al., EXCLI J 2025;24:690, 296,015 residents aged 11 and over, outcome first hospital admission with cancer; hazard ratio 1.23 (1.11 to 1.37) for at least one dose and 1.09 (1.02 to 1.16) for three or more; the authors call the findings "inevitably preliminary". Their critics and the cohort limits are in cvc-korea-cohort-bias-concerns and cvc-cohort-limits.
Would change if. a cohort with one common start date, a 6 to 12 month lag and a pre-specified outcome finds a hazard ratio clearly above 1 (the claim would strengthen), or the same design finds it at 1 (it would weaken); or the Seoul journal's investigation ends in a correction or retraction
Disputed by.
contested confidence low · our conclusion
The excess in the Seoul cohort is explained at least in part by how the two groups were defined and followed: different start dates, an unvaccinated control group with a cancer rate well below national figures, screening and surveillance differences, and many uncorrected subgroup tests.
Anchor. Locquet et al., Front Public Health 2026;14:1772406: different index dates (vaccination date against 1 Jan 2022) create "calendar time" bias without time-dependent or delayed-entry modelling; matching targets the effect in the vaccinated; 77.22 percent prior infection with no sensitivity analysis excluding it; surveillance bias for screened cancers (thyroid, breast, gastric, colorectal); 30 subgroup analyses uncorrected for multiplicity; "One-year solid tumor carcinogenesis does not seem biologically plausible"; asks for a lag of 6 to 12 months; rates the evidence low quality by GRADE. One author reports personal fees from pharmaceutical and diagnostic firms. Roccetti, AIMS Public Health 2026 (single author, benchmark audit): in the cohort 12.2 percent were aged 65 and over against 18 percent nationally, and cancer incidence in the unvaccinated aged 65 and over was 85.2 against 155.2 per 10,000 nationally (45.1 percent lower); argues a deflated control baseline inflates the hazard ratios. Our caveat: Roccetti compares a Seoul-only matched cohort with national figures and uses figures taken from the letter.
Would change if. the authors publish a reply or a re-analysis with a common start date, a lag period and delayed-entry modelling and the excess remains (the claim weakens) or disappears (it strengthens)
Disputed by.
proposed confidence provisional · our conclusion
COVID-19 vaccination causes unusually rapid or aggressive cancers (called "turbo cancer") in vaccinated people.
Anchor. Rests on case reports and clinical impressions. Etana Hecht's post of 4 Aug 2022 summarises an interview with Dr Ute Kruger, a pathologist, and says "Dr. Kruger initially thought that these turbo cancers, as she calls them, were due to delayed doctor appointments from Covid lockdowns, but that period is long over" (summary of an interview not watched here); Hecht calls the testimony "by nature anecdotal". Angus Dalgleish's written Senate testimony (3 Jun 2026) says he has "no doubt" the vaccine "likely played a significant role" in "these unexpected cancers"; the sentence follows his account of relapses and aggressive presentations in his own practice and a passage on cancer diagnoses disclosed by vaccinated public figures, and he adds that he raises this "not to imply certainty regarding any individual case". The testimony has no data tables. Case reports are in cvc-case-reports-no-denominator. No source read defines the term or measures it.
Would change if. a matched cohort that defines rapid progression in advance finds it clearly more common after vaccination, or a registry-linked analysis with individual vaccination status finds excess early-stage-to-advanced progression in vaccinated people
proposed confidence provisional · our conclusion
COVID-19 vaccination raises the risk of cancer in vaccinated people (in general, not only in the rapid form).
Anchor. Two cohorts report hazard ratios above 1 (cvc-korea-cohort-reports-excess, cvc-italy-cohort-lag), both disputed (cvc-korea-cohort-bias-concerns); one cell-line experiment (cvc-mechanism-spike-p53); mechanism reviews that name no tumour data (cvc-mechanism-other-hypotheses). In the Seoul cohort the overall hazard ratio is highest for adenoviral-vector vaccines (1.472) and lowest for mRNA only (1.199), the reverse of what an mRNA-specific mechanism would suggest, as our observation, not the authors' claim.
Would change if. a cohort with a common start date and a lag period replicates a clear excess, or a mechanism is shown in vaccinated animals or people
proposed confidence provisional · our conclusion
"Turbo cancer" is a recognised medical term for a defined kind of cancer.
Anchor. The phrase is in a small number of review papers: our Europe PMC phrase searches returned 5 or 6 hits (the two research streams counted differently; log L-09), none an epidemiological study. Szebeni (Pharmaceutics 2025, Oct) writes that the close timing of blood-cell cancers and vaccination led to the concept of 'turbo cancer', "a highly debated assertion on the acceleration of malignancy and rise in rapidly progressing new cancers following vaccinations", and that "This concept is not accepted by mainstream medicine"; the Eens authors write in their addendum that they "unequivocally disassociate ourselves from this term" and "nor do we recognize it as a legitimate medical term"; ASCO's written testimony says the appearance of late-stage aggressive tumours within weeks or months of an injection is "biologically incompatible" with decades of research on cancer causes.
Would change if. a published case definition for the term is adopted by a cancer society or tested in a cohort, or an oncology guideline uses it
proposed confidence low · our conclusion
In four observational cohorts of patients starting immune checkpoint inhibitors, those vaccinated against COVID-19 around the start of treatment had no worse survival than unvaccinated patients (hazard ratios 0.51 to 0.90 for death or survival); one cohort also reports more immune-related adverse events (hazard ratio 1.22), and the largest independent cohort found no significant association after 12 months.
Anchor. Grippin et al., Nature 2025;647:488-497: MD Anderson, 180 vaccinated within 100 days of starting immunotherapy and 704 not (the non-small-cell lung cohort; the paper also reports melanoma cohorts); adjusted for 39 covariates; median survival 20.6 against 37.3 months as printed, adjusted hazard ratio 0.51 (0.37 to 0.71); no benefit around chemotherapy alone or with influenza or pneumonia vaccines; mice and healthy volunteers show a rise in type I interferon. Single-centre cohort, retrospective. Nature Medicine 2026 (abstract): French national claims, 95,015 adults; pre-treatment mRNA vaccination hazard ratio for death 0.90 (0.87 to 0.94) at 1 to 3 months, 0.96 (0.93 to 1.00) at 6 months, "no significant association after 12 months", with "similar early patterns with non-mRNA COVID-19 and other adult vaccines" suggesting "modest, transient associations or healthy-vaccinee effects". European Journal of Cancer 2026 (abstract): 281 patients, 47 vaccinated, median 51.0 against 21.0 months, hazard ratio 0.615 (0.407 to 0.928). Journal for ImmunoTherapy of Cancer 2026 (abstract): 3,609 matched pairs, mortality hazard ratio 0.86 (0.80 to 0.93), immune-related adverse events 1.22 (1.17 to 1.28), severe 1.11, ICU admission 0.43.
Would change if. a prospective study or a cohort with a negative-control vaccine finds worse survival in vaccinated patients, or confirms a durable benefit
proposed confidence provisional · our conclusion
The shift toward IgG4 antibodies after repeated mRNA doses weakens the body's antibody defence against tumours.
Anchor. Irrgang et al., Sci Immunol 2023: the IgG4 share of spike-specific IgG rose from 0.04 percent after dose 2 to 19.27 percent after dose 3; not seen after adenoviral vaccines; reduced phagocytosis and complement activity. Our text search of this paper and of the 2024 Immunity and Ageing paper for "cancer", "tumor", "tumour" and "malignan" found no hits. Cell Reports 2025: spike IgG4 is "only inhibitory when directly competing with functional IgG subclasses" and cytotoxicity in plasma "was not depleted by adding a cocktail of Spike-specific IgG4 monoclonal antibodies". The link from IgG4 to tumours is borrowed from other literature (one mouse study cited by Gibo, not opened).
Would change if. a study shows spike-specific IgG4 impairing anti-tumour antibody effects in vaccinated people, or higher cancer incidence in people with higher IgG4 after vaccination
proposed confidence provisional · our conclusion
mRNA vaccination suppresses type I interferon signalling enough to impair cancer surveillance.
Anchor. Seneff et al., Food and Chemical Toxicology 2022;164:113008: a hypothesis and narrative review using VAERS counts and the literature, no tumour data. A 2023 letter (Barriere et al., FCT 178:113897) lists "major misunderstandings of the literature" and says VAERS was misused; a corrigendum to that letter was published 25 Sep 2026 (not read). Grippin et al. (Nature 2025) report the opposite direction, "a substantial increase in type I interferon" after COVID mRNA vaccines in mice and humans.
Would change if. measurements in vaccinated people show a lasting fall in interferon responses linked to tumour outcomes
proposed confidence provisional · our conclusion
COVID-19 vaccination causes cancer through one of several other proposed routes: spread of vaccine mRNA or spike to bone marrow with lymphopenia, microRNA in exosomes, spike binding oestrogen receptor alpha or BRCA and p53 proteins, integration of residual vaccine DNA, or promotion of dormant disease in a "multi-hit" model.
Anchor. Narrative reviews, in silico docking, in vitro work and case reports. Isidoro, Cancers 2025: "it appears extremely unlikely that SARS-CoV-2 and anti-COVID-19 mRNA vaccines elicit genotoxic events and cause neo-cancerogenesis in a short time", proposing non-genotoxic effects and writing "While a causal link cannot be established at this stage". Szebeni, Pharmaceutics 2025 (Oct): DNA integration evidence "is heavily argued in the cancer field". Valdes Angues and Perea Bustos, Cureus 2023, is a review; its conclusion urges caution for patients with cancer. EMA: no evidence linking residual plasmid DNA to side effects, and high-DNA claims "are based on results from unvalidated tests used by third parties". FDA (Marks): residual DNA fragments reaching the nucleus and chromosomes is "quite implausible". Underlying residual-DNA papers were not opened (cvc-sq-dna-contamination).
Would change if. integration of vaccine DNA into human cells, or tumour formation by it, is shown in vaccinated people or animals with validated assays
searched gap confidence provisional · result of a search
No controlled study we found defines rapid cancer progression, or aggressive cancer at diagnosis, in advance and compares it, or cancer recurrence, between vaccinated and unvaccinated people. The nearest are survival comparisons in patients starting immunotherapy.
Anchor. Searched PubMed and Europe PMC, 5 Oct 2026: "COVID-19 vaccination cancer risk cohort"; "turbo cancer COVID vaccine"; TITLE:"cancer" AND TITLE:"vaccinated" AND TITLE:"unvaccinated"; vaccination terms with Clalit or Israel; with Vaccine Safety Datalink or Kaiser; with Netherlands, Denmark, Sweden, Norway or Finland; "excess mortality" AND cancer AND COVID; and the citation lists of the Seoul, Pescara and Japanese papers. Hits were screened by title and abstract. None is a study whose primary outcome is rapid progression or recurrence by vaccination status outside immunotherapy cohorts (cvc-ici-patients-no-worse-survival). The one Vaccine Safety Datalink hit was a mortality study with no cancer outcome. A title and abstract screen can miss a study; the absence is a state of our search.
Would change if. a study of rapid progression or recurrence by vaccination status is published
Next step. Match vaccinated and unvaccinated adults newly diagnosed with the same cancer type and stage in a registry linked to vaccination records, define "rapid progression" before looking (stage shift, time to recurrence, survival by stage), and report it with a 6 to 12 month lag and a common start date (dt-rapid-progression-cohort).
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
Sub-question: was "turbo cancer" used about COVID-19 vaccines before 4 August 2022, as in an ar15.com comment of 30 November 2020 that Gorski cites?
Anchor. Gorski (secondary) gives the date and a quotation; we could not open the page. We found nothing earlier in a primary document.
Would change if. the comment is opened and says what Gorski reports, or an earlier use is found
Next step. Someone with access to ar15.com (403 to us, also via Wayback) can open the November 2020 thread and confirm the comment's date and wording.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
Sub-question: did Ute Kruger herself say "turbo cancers" in the Doctors for Covid Ethics interview of July 2022, and what did she report?
Anchor. Only Hecht's summary and two earlier write-ups were read; the video was not watched.
Would change if. the interview or her 18 Sep 2022 symposium talk (on archive.org) shows she used or did not use the term
Next step. Watch the interview and the symposium talk (archive.org item dr.-ute-kruger-covid-19-vaccination-observations-of-a-pathologist-2nd-medical-sy) and log what she said, with times.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
Sub-question: does the 2022 film "Died Suddenly" use the phrase "turbo cancer", and what does it say about cancer?
Anchor. Automated speech-to-text of a downloaded copy; the film is a venue for a general vaccine-cancer claim via DMED data, not a documented origin of the term. Lead Stories (secondary) reviewed the film for sudden death.
Would change if. a human viewing finds the phrase or a different account of the cancer segments
Next step. A person watches 22:00 to 27:00 of the 68-minute video and transcribes the cancer segments and speakers. Our automated transcript (base.en, error-prone) has no "turbo" and has cancer statements at about 22:08 and 25:34 (a military-doctor segment citing a "300% increase").
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
No cohort of cancer after COVID-19 vaccination from Kaiser or the Vaccine Safety Datalink, Israel, the Netherlands, the Nordic countries or the UK was found, beyond the Seoul and Pescara studies.
Anchor. PubMed and Europe PMC queries listed in cvc-rapid-progression-gap, 5 Oct 2026. The only Vaccine Safety Datalink hit was a mortality study in which cancer is an exclusion criterion. Absence from our searches is not proof none exists.
Would change if. such a cohort is found or published
Next step. Query the Vaccine Safety Datalink, Clalit, Danish and Swedish registers for cancer incidence by vaccination status with a lag period, and publish the analysis plan first.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
The main texts of the two Pfizer-BioNTech randomised trial reports report no cancer outcome, and their supplementary adverse-event tables were not opened, so malignancy counts by arm are unread.
Anchor. Text search of the open full text of Polack 2020 and Thomas 2021 for malignan, cancer, neoplasm and tumor: no cancer outcome in the main text.
Would change if. the supplementary tables or the FDA review show malignancy counts by arm
Next step. Read the supplementary adverse-event tables and the FDA clinical review for malignancy counts by arm; note the follow-up length (about 6 months) and when the placebo group was offered vaccine, which we did not verify.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
Does the French cohort of 28.7 million adults aged 18 to 59 (Semenzato et al., JAMA Network Open, Dec 2025) report lower cancer mortality in vaccinated people, as Sen. Blumenthal said?
Anchor. Abstract read; no copy retained, so the manifest entry has no sha256.
Would change if. the paper's cause-specific results are read
Next step. Read the full paper and its supplement for a cancer-specific mortality result (hazard ratio for all-cause death 0.75 over 4 years is in the abstract; the abstract says "regardless of the cause").
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
We found no WHO statement, no current CDC page and no UK (NHS, UKHSA, MHRA) statement that addresses whether COVID-19 vaccines cause cancer.
Anchor. WHO vaccine Q&A and the 49th GACVS report (March 2026) text-searched for cancer, turbo, malignan, residual DNA and SV40: no hits on causation. Archived CDC pages of 2023 contain no cancer statement.
Would change if. such a statement is found
Next step. Read current cdc.gov vaccine safety pages (403 to us), UKHSA and MHRA pages, Health Canada and the TGA. Absence of a statement is not an endorsement either way.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
England's national cancer registry figures for 2021 and 2022 (NHS England) were not read.
Anchor. digital.nhs.uk returned 403; the ONS 2023 deaths bulletin has no all-cancer age-standardised rate. England prostate and breast series were read as abstracts.
Would change if. the figures show a post-2021 all-cancer rise
Next step. Open the NHS England cancer registration statistics for 2021 and 2022 (403 to our proxy) and the Danish NORDCAN series.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
The residual-DNA papers behind the FDA and EMA statements and behind the 36 to 153-fold claim were not opened; this dig scopes the DNA-contamination question out.
Anchor. Statements read; underlying measurements not opened.
Would change if. the underlying papers contradict how the agencies and reviews describe them
Next step. Read the papers EMA cites (Kaiser et al., Vaccine 2025, PMID 40120438; Achs et al., npj Vaccines 2025) and the residual-DNA papers behind the slide claim (Kammerer et al.), as a separate dig.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
We did not re-run the retracted Japan paper's regression against current national data; this is scoped out.
Anchor. Only the paper's reported figures and the national series were compared.
Would change if. a re-run shows excess or none against a pre-specified method
Next step. Fit the 2010-2019 trend to the National Cancer Center series and test 2020-2024, with prediction intervals and a correction for the 2020 screening drop.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
What editorial action will Biomarker Research take on the Seoul letter after its notice of concern of 22 October 2025?
Anchor. Article page and PMC change history read 5 Oct 2026: notice present, no outcome; Crossref shows no update-to relation.
Would change if. the journal corrects, retracts or clears the letter
Next step. Re-read the article page and Crossref for an update; ask the editors.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
searched gap confidence provisional · result of a search
Why does the American Cancer Society page, revised 24 September 2025, no longer carry the 2024 statement that nothing suggests COVID-19 vaccines cause cancer?
Anchor. Text difference between the 2024 Wayback version and the live page noted; the ACS mRNA vaccines page (revised 29 Aug 2025) makes no causation statement.
Would change if. ACS says the removal was editorial or a change of position
Next step. Ask ACS; compare the Wayback versions between September 2024 and September 2025.
Start this step → (signs you in with GitHub; trusted contributors can send it to the dig agent)
Publication status is recorded only for sources someone looked up. A source with no status shown has not been checked for a retraction or correction; that is not the same as clean.
These pages are generated from plain YAML: claims.yaml · sources manifest. If you can show a finding is wrong, challenge it.